While current clinical trials for cardiac regeneration using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) employ immunosuppressive regimens used in heart transplants, the precise ...

Addition of 6 months of androgen deprivation therapy to stereotactic body radiotherapy more than doubled PFS in hormone-sensitive oligorecurrent prostate cancer. Nearly all patients treated with the ...

SAN DIEGO, Dec. 9, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that they will ...

A new study led by researchers at National Jewish Health has revealed that, while a wide range of viruses can cause lower respiratory tract illnesses (LRIs) in infants, certain viruses and viral ...

Results from sub-study 03A of KEYMAKER-U03, an international, open-label, rolling-arm, phase I/II umbrella trial, spotlight the promise of pembrolizumab-based regimens combined with tyrosine kinase ...

SEATTLE -- Once-weekly navepegritide and lonapegsomatropin boosted growth in children with achondroplasia, the most common form of dwarfism, according to interim findings from a small phase II trial.

There are quite a few locked safes that you'll encounter throughout Mafia: The Old Country. Some of these are required to progress the main story, while others are ...

OpenAI has launched a new “study mode” for ChatGPT that’s designed to help students better understand complex topics—but instead of dishing out direct answers, study mode employs the Socratic method ...

OpenAI is rolling out a new Study Mode the company says is designed to give students a better understanding of complex topics. Like Claude's Learning Mode, which Anthropic introduced in April, Study ...

The treatment, known as CagriSema, combines two hormone-based drugs — semaglutide, already approved for weight loss, and cagrilintide, which is still being studied. Cagrilintide is a long-acting form ...

Corbus Pharmaceuticals initiates combination cohort of CRB-701 study for solid tumors, focusing on HNSCC and cervical cancer. Data update expected this year. Corbus Pharmaceuticals Holdings, Inc.